Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Stannsoporfin - InfaCare Pharmaceuticals

Drug Profile

Stannsoporfin - InfaCare Pharmaceuticals

Alternative Names: Sn-mesoporphyrin; Stanate; tin-mesoporphyrin; Torcan

Latest Information Update: 28 Aug 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rockefeller University
  • Developer InfaCare Pharmaceutical Corporation; National Hospital of Pediatrics
  • Class Antirheumatics; Heavy metals; Hepatoprotectants; Mesoporphyrins
  • Mechanism of Action Decyclizing heme oxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Hyperbilirubinaemia

Most Recent Events

  • 22 Aug 2018 Mallinckrodt receives complete response letter from the US FDA for stannsoporfin in Hyperbilirubinaemia (In neonates)
  • 24 Jun 2018 Biomarkers information updated
  • 03 May 2018 The US FDA's Gastrointestinal Drugs Advisory Committee and Paediatric Advisory Committee votes 21 to 3 that risk-benefit profile of stannsoporfin does not support approval for the treatment of Hyperbilirubinaemia (In neonates)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top